ATYRHIGH SIGNALRISK10-K

ATYR's Phase 3 EFZO-FIT study for efzofitimod in pulmonary sarcoidosis has concluded with results that appear unsuccessful, as the company now emphasizes the lack of established FDA regulatory pathways and warns that failed Phase 3 trials may not support approval.

The language changes reveal a dramatic shift from promoting positive Phase 1b/2a results and FDA engagement to highlighting regulatory uncertainties and Phase 3 failure risks, strongly suggesting the EFZO-FIT study did not meet its primary endpoint. This represents a major setback for ATYR's lead drug candidate and core development program, likely forcing the company to reassess its regulatory strategy and potentially seek alternative development paths.

Comparing 2026-03-05 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows a deteriorating company burning through more cash, with net losses widening 15.8% to $74.1M despite a 10.3% improvement in operating cash flow to -$62.0M. R&D expenses increased 10.8% to $60.2M while revenue declined 19.1% to just $190K, reflecting a development-stage biotech that increased spending on what appears to be an unsuccessful Phase 3 trial. The 10.4% increase in outstanding shares from 88.9M to 98.1M indicates the company raised additional capital, likely to fund operations through the clinical failure.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
-19.1%
$235K→$190K

Revenue softened 19.1% — monitor whether this is cyclical or structural.

Net Income
P&L
-15.8%
-$64.0M→-$74.1M

Net income declined 15.8% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-14.3%
-$67.9M→-$77.6M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

R&D Expense
P&L
+10.8%
$54.4M→$60.2M

R&D investment increased 10.8% — signals commitment to future product development, though near-term margin impact.

Operating Cash Flow
Cash Flow
+10.3%
-$69.1M→-$62.0M

Operating cash flow grew 10.3% — strong conversion of earnings to cash, healthy business fundamentals.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-03-13
ADDED
The number of outstanding shares of the registrant s common stock, par value $0.001 per share, as of March 2, 2026 was 98,051,212 .
Some of the more significant risks we face include the following: There is no established U.S.
Food and Drug Administration (FDA) regulatory pathway for approval of a drug in pulmonary sarcoidosis.
In addition, a Phase 3 clinical trial that does not meet its primary endpoint may not support an FDA regulatory pathway for approval.
In September 2025, we announced top-line data from a global Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis (the EFZO-FIT study).
The EFZO-FIT study was a 52-week study in 268 patients with pulmonary sarcoidosis consisting of three parallel cohorts randomized equally to either 3.0 mg/kg or 5.0 mg/kg of efzofitimod or placebo dosed intravenously once every four weeks for a total of 12 doses, with a 4-week safety follow-up.
The study design incorporated a protocol guided steroid taper in the first 12 weeks of the study, followed by continued taper or rescue until week 48.
The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48.
The change from baseline in mean daily OCS dose reduced to an average of 2.79 mg for 5.0 mg/kg efzofitimod vs 3.52 mg for placebo (p=0.3313).
The study s statistical analysis plan was designed on a hierarchical assessment basis, as such since the primary endpoint was not met, all subsequent statistical testing is reported as nominal findings.
REMOVED
The number of outstanding shares of the registrant s common stock, par value $0.001 per share, as of March 7, 2025 was 88,858,612 .
In September 2021, we announced positive results and clinical proof-of-concept from a double-blind, placebo-controlled Phase 1b/2a clinical trial in 37 patients with pulmonary sarcoidosis.
The study was designed to evaluate the safety, tolerability, immunogenicity and preliminary efficacy of three doses of intravenous (IV) efzofitimod, 1.0, 3.0 and 5.0 mg/kg, in the context of a forced steroid taper.
Efzofitimod was safe and well-tolerated at all doses administered with no serious drug-related adverse events or signal of immunogenicity.
In February 2022, we met with the FDA in an end-of-Phase 2 meeting to discuss our plans for subsequent clinical development and path to registration for efzofitimod for pulmonary sarcoidosis.
Subsequently, we initiated a global pivotal Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis (the EFZO-FIT study).
The EFZO-FIT study is a 52-week study consisting of three parallel cohorts randomized equally to either 3.0 mg/kg or 5.0 mg/kg of efzofitimod or placebo dosed intravenously once a month for a total of 12 doses.
We expected the study to enroll up to 264 subjects with pulmonary sarcoidosis at multiple centers in the United States, Europe, Brazil, and Japan.
Secondary endpoints include measures of lung function assessed by forced vital capacity (FVC) and health-related quality of life assessments and questionnaires (KSQ lung score).
During 2023 and 2024, we have had data and safety monitoring board (DSMB) reviews of our EFZO-FIT study.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →